Celcuity(CELC)
$60.57-3.80 (-5.90%)
CELC
Celcuity stock drug pipeline
$60.57
At close:-3.80 (-5.90%)
Want to see CELC full AI Analyst Report?
Celcuity (CELC) Drug Pipeline
565 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Arm A: Gedatolisib + Palbociclib Or Ribociclib + Fulvestrant, Arm B: Palbociclib Or Ribociclib + Fulvestrant | Breast Cancer | Phase III | Recruiting | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Dec 24, 2024 | ― |
| Darolutamide, Gedatolisib | Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Mcrpc (Metastatic Castration-Resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease | phase1AndPhase2 | Recruiting | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | Dec 13, 2023 | ― |
| Fulvestrant, Palbociclib, Alpelisib, Gedatolisib | Breast Cancer | Phase III | Recruiting | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | Aug 12, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Arm A: Gedatolisib + Palbociclib Or Ribociclib + Fulvestrant, Arm B: Palbociclib Or Ribociclib + Fulvestrant | Phase III | Breast Cancer | Recruiting | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Dec 24, 2024 | ― |
| Darolutamide, Gedatolisib | phase1AndPhase2 | Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Mcrpc (Metastatic Castration-Resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease | Recruiting | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | Dec 13, 2023 | ― |
| Fulvestrant, Palbociclib, Alpelisib, Gedatolisib | Phase III | Breast Cancer | Recruiting | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) | Aug 12, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Celcuity Inc. (CELC) have in its pipeline
Celcuity CELC is currently developing the following drugs: Arm A: Gedatolisib + Palbociclib Or Ribociclib + Fulvestrant, Arm B: Palbociclib Or Ribociclib + Fulvestrant, Darolutamide, Gedatolisib, Fulvestrant, Palbociclib, Alpelisib, Gedatolisib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

